Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JMA to Dispatch JMATs to Disaster Area
March 28, 2011
- Both AZ, Plaintiffs Appeal to High Court
March 28, 2011
- NIRS Dispatches 3 Teams to Fukushima
March 28, 2011
- JAMS to Promote Industry-Academia Alliances by Increasing COI Transparency
March 28, 2011
- Insulin Manufacturers Ensure Stable Supply of Their Products
March 28, 2011
- Astellas Applies for Marketing Approval for Bixalomer
March 28, 2011
- Domestic, Foreign Drugmakers Up Efforts to Assist Quake Victims
March 28, 2011
- Wholesalers Striving to Fulfill Mission despite Risk
March 28, 2011
- Exal Approved for LCH as Additional Indication: Nippon Kayaku
March 28, 2011
- 2 Treatments Recommended for Approval as Senshin-iryo
March 28, 2011
- Yakult Licenses Perifosine from Aeterna Zentaris
March 21, 2011
- Kyowa Kirin Begins PIII for Pegfilgrastim
March 21, 2011
- Pfizer to Enhance Focus on Infectious Diseases
March 21, 2011
- Janssen Begins PIII Trial of Concerta for AD/HD in Adults
March 21, 2011
- Analysts Question Kyowa Kirin's Acquisition of ProStrakan
March 21, 2011
- MediciNova Obtains Patent on Ibudilast to Treat Drug Dependence
March 21, 2011
- Carna Biosciences to Accelerate Licensing of Its Own Compounds
March 21, 2011
- PIII Results for Halaven to Be Published in The Lancet
March 21, 2011
- Citigroup Sees Strong Outlook for Nippon Shinyaku's Vidaza
March 21, 2011
- Pfizer, Daiichi Sankyo Alert Med. Institutions about Use of Prevnar, ActHIB
March 21, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…